Related references
Note: Only part of the references are listed.Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Sara Malik et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Unlocking the Health Potential of Microalgae as Sustainable Sources of Bioactive Compounds
Assunta Saide et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Rea et al.
BLOOD (2021)
Bioactivity Screening of Antarctic Sponges Reveals Anticancer Activity and Potential Cell Death via Ferroptosis by Mycalols
Gennaro Riccio et al.
MARINE DRUGS (2021)
Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
Vanessa Innao et al.
CURRENT ONCOLOGY (2021)
The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti-Passerini et al.
FUTURE ONCOLOGY (2020)
DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
Henning D. Popp et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Novel therapeutic approaches in chronic myeloid leukemia
Nurgul Ozgur Yurttas et al.
LEUKEMIA RESEARCH (2020)
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti et al.
ACTA HAEMATOLOGICA (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Recent advances of oncolytic virus in cancer therapy
Moumita Mondal et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
First evidence of anticancer and antimicrobial activity in Mediterranean mesopelagic species
Chiara Lauritano et al.
SCIENTIFIC REPORTS (2020)
Pheophorbide a: State of the Art
Assunta Saide et al.
MARINE DRUGS (2020)
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission
Philippe Rousselot et al.
BLOOD ADVANCES (2020)
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Claudia Vener et al.
BLOOD ADVANCES (2020)
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
Ehab Atallah et al.
HAEMATOLOGICA (2020)
Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
Qian Jiang et al.
BLOOD (2020)
Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
Elisabetta Abruzzese et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
Chodimella Chandrasekhar et al.
SCIENTIFIC REPORTS (2019)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia
Orlando Antelope et al.
EXPERIMENTAL HEMATOLOGY (2019)
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Federica Loscocco et al.
FRONTIERS IN ONCOLOGY (2019)
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
Anna G. Turkina et al.
BLOOD (2019)
Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy
Jorge E. Cortes et al.
BLOOD (2019)
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
Brian A. Jonas et al.
LEUKEMIA (2019)
Management of Chronic Myeloid Leukemia in Advanced Phase
Massimiliano Bonifacio et al.
FRONTIERS IN ONCOLOGY (2019)
Caprine herpesvirus 1 (CpHV-1) as a potential candidate for oncolytic virotherapy
Serena Montagnaro et al.
CANCER BIOLOGY & THERAPY (2019)
An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
Qian Jiang et al.
BLOOD (2019)
Nilotinib in the treatment of chronic myeloid leukemia
Tomasz Sacha et al.
FUTURE ONCOLOGY (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Preetesh Jain et al.
BLOOD ADVANCES (2019)
The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker
Ka-Won Kang et al.
ANTICANCER RESEARCH (2018)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option
Alessandra Iurlo et al.
CLINICAL DRUG INVESTIGATION (2018)
Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia
Ayalew Tefferi
HEMATOLOGICAL ONCOLOGY (2018)
Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells
Sara Damiano et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Marine Microalgae with Anti-Cancer Properties
Kevin A. Martinez Andrade et al.
MARINE DRUGS (2018)
Breaking down Leukemia Walls: Heteronemin, a Sesterterpene Derivative, Induces Apoptosis in Leukemia Molt4 Cells through Oxidative Stress, Mitochondrial Dysfunction and Induction of Talin Expression
Yu-Cheng Chen et al.
MARINE DRUGS (2018)
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
Michele Massimino et al.
MOLECULAR CANCER (2018)
Zebrafish-based identification of the antiseizure nucleoside inosine from the marine diatom Skeletonema marinoi
Theo Brillatz et al.
PLOS ONE (2018)
Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model
Kseniya S. Yurchenko et al.
PLOS ONE (2018)
Curcumin differentially affects cell cycle and cell death in acute and chronic myeloid leukemia cells
Macario Martinez-Castillo et al.
ONCOLOGY LETTERS (2018)
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
Elena Arrigoni et al.
STEM CELLS TRANSLATIONAL MEDICINE (2018)
Ponatinib: A Review of Efficacy and Safety
Fulvio Massaro et al.
CURRENT CANCER DRUG TARGETS (2018)
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
Kendra Sweet et al.
LEUKEMIA RESEARCH (2018)
Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy
Anna G. Turkina et al.
BLOOD (2018)
Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro
Li Li et al.
ACTA PHARMACOLOGICA SINICA (2018)
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Philippe Rousselot et al.
CANCER (2017)
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors
Michiyo Asano et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Marine microorganisms as a promising and sustainable source of bioactive molecules
G. Romano et al.
MARINE ENVIRONMENTAL RESEARCH (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
The first total synthesis of the marine acetylenic alcohol, lembehyne B - a selective inducer of early apoptosis in leukemia cancer cells
Lilya U. Dzhemileva et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth
Daniele Bellavia et al.
THERANOSTICS (2017)
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Jae-Yong Kwak et al.
CLINICAL CANCER RESEARCH (2017)
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Ahmet Emre Eskazan et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management
Jorge E. Cortes et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia
Roberto Ciarcia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
Screening of new antileukemic agents from essential oils of algae extracts and computational modeling of their interactions with intracellular signaling nodes
Belkis Ataseyer-Arslan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
The marine biodiscovery pipeline and ocean medicines of tomorrow
Marcel Jaspars et al.
JOURNAL OF THE MARINE BIOLOGICAL ASSOCIATION OF THE UNITED KINGDOM (2016)
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Recent advances in oncolytic adenovirus therapies for cancer
Amanda Rosewell Shaw et al.
CURRENT OPINION IN VIROLOGY (2016)
Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation
Xin-pin Wu et al.
ACTA PHARMACOLOGICA SINICA (2015)
Epidemiology of chronic myeloid leukaemia: an update
Martin Hoglund et al.
ANNALS OF HEMATOLOGY (2015)
Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up
Jorge E. Cortes et al.
CANCER (2015)
Reactive oxygen species in redox cancer therapy
Lingying Tong et al.
CANCER LETTERS (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment
Joanna Gora-Tybor et al.
LEUKEMIA & LYMPHOMA (2015)
Oncolytic parvoviruses: from basic virology to clinical applications
Antonio Marchini et al.
VIROLOGY JOURNAL (2015)
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21
Simona Taverna et al.
ONCOTARGET (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Lixian Wu et al.
CLINICAL CANCER RESEARCH (2015)
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
Oliver G. Ottmann et al.
BLOOD (2015)
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro
Li-xian Wu et al.
ACTA PHARMACOLOGICA SINICA (2014)
Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
Elisabetta Abruzzese et al.
BIODRUGS (2014)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
Sheridan M. Hoy
DRUGS (2014)
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
Sung-Hyun Kim et al.
HAEMATOLOGICA (2014)
Suvanine Sesterterpenes and Deacyl Irciniasulfonic Acids from a Tropical Coscinoderma sp Sponge
Chang-Kwon Kim et al.
JOURNAL OF NATURAL PRODUCTS (2014)
New Cyclic Cystine Bridged Peptides from the Sponge Suberites waedoensis
Jinhaeng Song et al.
MARINE DRUGS (2014)
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
J. F. Seymour et al.
BLOOD CANCER JOURNAL (2014)
Adding a new facet to STAT5 in CML Multitasking for leukemic cells
Wolfgang Warsch et al.
CELL CYCLE (2013)
Extracellular vesicles: Exosomes, microvesicles, and friends
Graca Raposo et al.
JOURNAL OF CELL BIOLOGY (2013)
Gombamide A, a Cyclic Thiopeptide from the Sponge Clathria gombawuiensis
Jung-Kyun Woo et al.
JOURNAL OF NATURAL PRODUCTS (2013)
Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice
M. Nieborowska-Skorska et al.
LEUKEMIA (2013)
Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia
Yin Tong et al.
ONCOTARGET (2013)
Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
Wesam Ahmed et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Biology and significance of the JAK/STAT signalling pathways
Hiu Kiu et al.
GROWTH FACTORS (2012)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia
Andreas Hochhaus et al.
CELL CYCLE (2011)
Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 Cells
Meihua Jin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
Tomasz Skorski
LEUKEMIA & LYMPHOMA (2011)
Epigenomics of leukemia: from mechanisms to therapeutic applications
Cristina Florean et al.
EPIGENOMICS (2011)
Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia
Veena S Ghalaut et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang et al.
CANCER CELL (2010)
Bovine herpesvirus type 1 as a novel oncolytic virus
R. Rodrigues et al.
CANCER GENE THERAPY (2010)
Dysregulated Calcium Homeostasis and Oxidative Stress in Chronic Myeloid Leukemia (CML) Cells
Roberto Ciarcia et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Chronic myeloid leukemia: mechanisms of blastic transformation
Danilo Perrotti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Photosynthetic marine organisms as a source of anticancer compounds
F. Folmer et al.
PHYTOCHEMISTRY REVIEWS (2010)
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Susan Branford et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Armed replicating adenoviruses for cancer virotherapy
J. J. Cody et al.
CANCER GENE THERAPY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2008)
Smenospongine, a Sesquiterpene Aminoquinone from a Marine Sponge, Induces G1 Arrest or Apoptosis in Different Leukemia Cells
Dexin Kong et al.
Marine Drugs (2008)
OXIDATIVE STRESS AND ANTIOXIDANT STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Rizwan Ahmad et al.
INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY (2008)
Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications
C. Alarcn de la Lastral et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
Jorge Cortes et al.
CANCER (2007)
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
Jorge Cortes et al.
CANCER (2007)
Herpes simplex virus 1 (HSV-1) for cancer treatment
Y. Shen et al.
CANCER GENE THERAPY (2006)
Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience
GM Cragg et al.
JOURNAL OF NATURAL PRODUCTS (2006)
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
G Borthakur et al.
CANCER (2006)
Effect of resveratrol on high glucose-induced stress in human leukemia K562 cells
WH Chan
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Development of farnesyl transferase inhibitors: A review
NMGM Appels et al.
ONCOLOGIST (2005)
Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance
A Hochhaus et al.
LEUKEMIA (2004)
Results of decitabine (5-Aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
HM Kantarjian et al.
CANCER (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
J Cortes et al.
BLOOD (2003)
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
S Roumiantsev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Structure-activity relationship of neuritogenic spongean acetylene alcohols, lembehynes
S Aoki et al.
TETRAHEDRON (2002)
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
D Kirn et al.
NATURE MEDICINE (2001)
Share Paper
